These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
283 related articles for article (PubMed ID: 9462430)
1. Concentration-dependent killing of antibiotic-resistant pneumococci by the methoxyquinolone moxifloxacin. Klugman KP; Capper T J Antimicrob Chemother; 1997 Dec; 40(6):797-802. PubMed ID: 9462430 [TBL] [Abstract][Full Text] [Related]
2. Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents. Hoellman DB; Lin G; Jacobs MR; Appelbaum PC J Antimicrob Chemother; 1999 May; 43(5):645-9. PubMed ID: 10382885 [TBL] [Abstract][Full Text] [Related]
3. Activity of moxifloxacin and twelve other antimicrobial agents against 216 clinical isolates of Streptococcus pneumoniae. Esposito S; Noviello S; Ianniello F Chemotherapy; 2001; 47(2):90-6. PubMed ID: 11173809 [TBL] [Abstract][Full Text] [Related]
4. Antipneumococcal activity of BAY 12-8039, a new quinolone, compared with activities of three other quinolones and four oral beta-lactams. Visalli MA; Jacobs MR; Appelbaum PC Antimicrob Agents Chemother; 1997 Dec; 41(12):2786-9. PubMed ID: 9420061 [TBL] [Abstract][Full Text] [Related]
5. Susceptibility of twenty penicillin-susceptible and -resistant pneumococci to levofloxacin, ciprofloxacin, ofloxacin, erythromycin, azithromycin, and clarithromycin by MIC and time-kill. Visalli MA; Jacobs MR; Appelbaum PC Diagn Microbiol Infect Dis; 1997 Jul; 28(3):131-7. PubMed ID: 9294703 [TBL] [Abstract][Full Text] [Related]
6. Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents. Kosowska-Shick K; Credito K; Pankuch GA; Lin G; Bozdogan B; McGhee P; Dewasse B; Choi DR; Ryu JM; Appelbaum PC Antimicrob Agents Chemother; 2006 Jun; 50(6):2064-71. PubMed ID: 16723567 [TBL] [Abstract][Full Text] [Related]
7. In vitro activity of BAY 12-8039, a new fluoroquinolone, against species representative of respiratory tract pathogens. Souli M; Wennersten CB; Eliopoulos GM Int J Antimicrob Agents; 1998 Apr; 10(1):23-30. PubMed ID: 9624540 [TBL] [Abstract][Full Text] [Related]
8. Antipneumococcal activity of DK-507k, a new quinolone, compared with the activities of 10 other agents. Browne FA; Bozdogan B; Clark C; Kelly LM; Ednie L; Kosowska K; Dewasse B; Jacobs MR; Appelbaum PC Antimicrob Agents Chemother; 2003 Dec; 47(12):3815-24. PubMed ID: 14638489 [TBL] [Abstract][Full Text] [Related]
9. Comparative in-vitro activity of moxifloxacin, penicillin, ceftriaxone and ciprofloxacin against pneumococci isolated from meningitis. Tarasi A; Capone A; Tarasi D; Cassone M; Bianco G; Venditti M J Antimicrob Chemother; 1999 Jun; 43(6):833-5. PubMed ID: 10404324 [TBL] [Abstract][Full Text] [Related]
10. Antipneumococcal activities of gemifloxacin compared to those of nine other agents. Davies TA; Kelly LM; Pankuch GA; Credito KL; Jacobs MR; Appelbaum PC Antimicrob Agents Chemother; 2000 Feb; 44(2):304-10. PubMed ID: 10639354 [TBL] [Abstract][Full Text] [Related]
11. Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology. Pankuch GA; Jacobs MR; Appelbaum PC Antimicrob Agents Chemother; 1994 Sep; 38(9):2065-72. PubMed ID: 7811020 [TBL] [Abstract][Full Text] [Related]
13. Moxifloxacin: a comparison with other antimicrobial agents of in-vitro activity against Streptococcus pneumoniae. Reinert RR; Schlaeger JJ; Lütticken R J Antimicrob Chemother; 1998 Dec; 42(6):803-6. PubMed ID: 10052905 [TBL] [Abstract][Full Text] [Related]
14. Activity of moxifloxacin and other quinolones against pneumococci resistant to first-line agents, or with high-level ciprofloxacin resistance. Johnson AP; Warner M; Livermore DM Int J Antimicrob Agents; 2001 May; 17(5):377-81. PubMed ID: 11337224 [TBL] [Abstract][Full Text] [Related]
15. Bactericidal activity of moxifloxacin compared to grepafloxacin and clarithromycin against Streptococcus pneumoniae and Streptococcus pyogenes investigated using an in vitro pharmacodynamic model. Esposito S; Noviello S; Ianniello F J Chemother; 2000 Dec; 12(6):475-81. PubMed ID: 11154028 [TBL] [Abstract][Full Text] [Related]
16. MIC and time-kill study of activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible and -resistant pneumococci. Visalli MA; Jacobs MR; Appelbaum PC Antimicrob Agents Chemother; 1996 Feb; 40(2):362-6. PubMed ID: 8834881 [TBL] [Abstract][Full Text] [Related]
17. In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis. Jones RN; Ballow CH; Schentag JJ; Johnson DM; Deinhart JA Diagn Microbiol Infect Dis; 1998 May; 31(1):313-25. PubMed ID: 9597392 [TBL] [Abstract][Full Text] [Related]
18. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens. Noviello S; Ianniello F; Leone S; Esposito S J Antimicrob Chemother; 2003 Nov; 52(5):869-72. PubMed ID: 14519672 [TBL] [Abstract][Full Text] [Related]
19. Activity of oral agents against pediatric isolates of Streptococcus pneumoniae. Black J; Moland ES; Chartrand SA; Thomson KS Diagn Microbiol Infect Dis; 2001 Mar; 39(3):195-7. PubMed ID: 11337189 [TBL] [Abstract][Full Text] [Related]
20. Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae. Saravolatz L; Manzor O; Check C; Pawlak J; Belian B J Antimicrob Chemother; 2001 Jun; 47(6):875-7. PubMed ID: 11389122 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]